Followers | 9 |
Posts | 740 |
Boards Moderated | 0 |
Alias Born | 10/06/2010 |
Thursday, June 19, 2014 2:02:00 PM
As has been the case for KBLB since inception IMO, Kim has been focused on the process (albeit boring at most times) first and foremost before hyping and selling the outcome. Of course the outcome is why we're here, but a lot of companies sell their shares based on what will happen without setting up the infrastructure to support their hype.
We've seen Kim Thompson set up with the University that not just had genes sequences, but patents on them. He has chosen leaders in their respective fields for advice and for hands on research. He adapted and folded in Zinc Fingers to speed up the process up as he secured Licensing from Sigma Aldrich. He gets MOU's signed for potential suitors, files and upkeeps Trademarks, re-signs agreements and maintains business relationships with Notre Dame and Wyoming, and even set up a meeting with shareholders to be face to face. It's truly visible by his actions that infrastructure is extremely important to Kim Thompson and with that strong foundation this company can flourish. It's an extreme balancing act to raise and maintain funds/SP for a project that needs so much time and has so many boring parts to it (test weaving, product consistency, hatch rate monitoring, production scaling, silkworm trait consistency markers..) . I think Kim has done a great job overall (not perfect by any means, I've had my REALISTIC gripes along the way) to keep KBLB moving in the right direction and in the right way.
GO KBLB.
Very happy with the latest news!!
Everything I say is my own opinion and should not be taken as direct investment advice. Do your own DD and make your own decisions.
Recent KBLB News
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/22/2023 09:31:54 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/16/2023 09:30:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:43:51 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/11/2023 08:30:50 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/08/2023 04:15:15 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 09/01/2023 08:30:52 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:35:05 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM